Quick Answer
CNBX Pharmaceuticals Inc. reported Net Income Loss of -$314.0 thousand for the year ending 2025.
- CNBX Pharmaceuticals Inc. showed an increase of +54.8% in Net Income Loss from 2024 to 2025.
- This data is from CNBX Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on December 1, 2025.
- XBRL data for this metric is available from 2005 to 2025 (21 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 21 years of available data (2005 to 2025), CNBX Pharmaceuticals Inc.'s Net Income Loss has declined by 17,343.1%.
- Historical annual values: Fiscal year 2025: -$314.0 thousand | Fiscal year 2024: -$695.2 thousand | Fiscal year 2023: -$3.71 million | Fiscal year 2022: -$3.72 million | Fiscal year 2021: -$3.19 million | Fiscal year 2020: -$7.47 million | Fiscal year 2019: $1.13 million | Fiscal year 2018: -$3.78 million | Fiscal year 2017: -$1.93 million | Fiscal year 2016: -$307.2 thousand | Fiscal year 2015: -$541.4 thousand | Fiscal year 2014: -$270.0 thousand | Fiscal year 2013: -$56.4 thousand | Fiscal year 2012: -$1.7 thousand | Fiscal year 2011: -$107.3 thousand | Fiscal year 2010: -$115.0 thousand | Fiscal year 2009: -$114.9 thousand | Fiscal year 2008: -$27.5 thousand | Fiscal year 2007: -$23.2 thousand | Fiscal year 2006: -$20.0 thousand | Fiscal year 2005: -$1.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: